# A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

> **NCT05362045** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 158 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Mavacamten

## Key facts

- **NCT ID:** NCT05362045
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-16
- **Primary completion:** 2022-08-19
- **Final completion:** 2022-08-19
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2022-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05362045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05362045, "A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05362045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*